Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Conlon

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
Investigational New Drugs|February 4, 2018
The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cellsAlexandra Canonici, Zulfiqar Qadir, Neil T Conlon, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 17, 2024
Distal Immunization and Systemic Cytokines Establish a Transient Immune Alert State in the IntestineYixuan Wu, Jessica Y Huang, Michael T Conlon, et al.
The Journal of Infectious Diseases|March 1, 1986
Clinical evaluation of the immunoadjuvant murabutide, a derivative of MDP, administered with a tetanus toxoid vaccineE Telzak, S M Wolff, C A Dinarello, et al.
The AAPS Journal|October 13, 2022
FOLFIRINOX Pharmacodynamic Interactions in 2D and 3D Pancreatic Cancer Cell CulturesTaylor J Allen-Coyle, Jin Niu, Eva Welsch, et al.
Virus Research|March 26, 2025
Analysis of polyclonal and monoclonal antibody to the influenza virus nucleoprotein in different oligomeric statesMallory L Myers, Michael T Conlon, John R Gallagher, et al.
Biorxiv : the Preprint Server for Biology|October 7, 2024
Analysis of polyclonal and monoclonal antibody to the influenza virus nucleoprotein in different oligomeric statesMallory L Myers, Michael T Conlon, John R Gallagher, et al.
Investigational New Drugs|August 1, 2018
HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancerAlexandra Canonici, Laura Ivers, Neil T Conlon, et al.
Molecular Cancer|June 25, 2014
PP2A inhibition overcomes acquired resistance to HER2 targeted therapyMartina Sj McDermott, Brigid C Browne, Neil T Conlon, et al.
Molecular Cancer|November 2, 2023
Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapyMartina S J McDermott, Brigid C Browne, Neil T Conlon, et al.
Science (New York, N.Y.)|June 1, 1979
Voyager 1: energetic ions and electrons in the jovian magnetosphereR E Vogt, W R Cook, A C Cummings, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
Investigational New Drugs|February 4, 2018
The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cellsAlexandra Canonici, Zulfiqar Qadir, Neil T Conlon, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 17, 2024
Distal Immunization and Systemic Cytokines Establish a Transient Immune Alert State in the IntestineYixuan Wu, Jessica Y Huang, Michael T Conlon, et al.
The Journal of Infectious Diseases|March 1, 1986
Clinical evaluation of the immunoadjuvant murabutide, a derivative of MDP, administered with a tetanus toxoid vaccineE Telzak, S M Wolff, C A Dinarello, et al.
The AAPS Journal|October 13, 2022
FOLFIRINOX Pharmacodynamic Interactions in 2D and 3D Pancreatic Cancer Cell CulturesTaylor J Allen-Coyle, Jin Niu, Eva Welsch, et al.
Virus Research|March 26, 2025
Analysis of polyclonal and monoclonal antibody to the influenza virus nucleoprotein in different oligomeric statesMallory L Myers, Michael T Conlon, John R Gallagher, et al.
Biorxiv : the Preprint Server for Biology|October 7, 2024
Analysis of polyclonal and monoclonal antibody to the influenza virus nucleoprotein in different oligomeric statesMallory L Myers, Michael T Conlon, John R Gallagher, et al.
Investigational New Drugs|August 1, 2018
HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancerAlexandra Canonici, Laura Ivers, Neil T Conlon, et al.
Molecular Cancer|June 25, 2014
PP2A inhibition overcomes acquired resistance to HER2 targeted therapyMartina Sj McDermott, Brigid C Browne, Neil T Conlon, et al.
Molecular Cancer|November 2, 2023
Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapyMartina S J McDermott, Brigid C Browne, Neil T Conlon, et al.
Science (New York, N.Y.)|June 1, 1979
Voyager 1: energetic ions and electrons in the jovian magnetosphereR E Vogt, W R Cook, A C Cummings, et al.
Pageof 5